Pressmeddelanden från Zealand Pharma

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

I förrgår 19:45

Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity 19 feb 14:00

Zealand Pharma convenes its Annual General Meeting 2026 19 feb 07:00

Zealand Pharma Announces Financial Results for the Full Year 2025 18 feb 07:30

Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 12 feb 17:01

Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results 09 jan 08:00

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy 05 jan 17:05

Zealand Pharma to present at the J.P. Morgan Healthcare Conference 31 dec 2025 17:05

Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 19 dec 2025 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 11 dec 2025 22:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 11 dec 2025 07:05

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health 11 dec 2025 07:00

Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases 05 dec 2025 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 01 dec 2025 17:00

REMINDER: Zealand Pharma’s Capital Markets Day on December 11, 2025 12 nov 2025 17:30

Zealand Pharma to participate in the Jefferies Global Healthcare Conference 06 nov 2025 17:30

Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results 17 okt 2025 17:05

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.30 sep 2025 17:05

Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 24 sep 2025 17:00

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations 11 sep 2025 22:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 11 sep 2025 17:00

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 28 aug 2025 17:00

Zealand Pharma to participate in upcoming investor conferences in September 2025 20 aug 2025 22:00

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.14 aug 2025 07:00

Zealand Pharma Announces Financial Results for the First Half of 2025 07 aug 2025 17:30

Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results 18 jul 2025 18:30

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.30 jun 2025 17:05

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 18 jun 2025 17:29

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide 06 jun 2025 22:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 27 maj 2025 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 19 maj 2025 15:00

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer 12 maj 2025 07:00

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 09 maj 2025 06:25

Zealand Pharma announces closing of collaboration and license agreement with Roche 08 maj 2025 07:00

Zealand Pharma Announces Financial Results for the First Three Months of 2025 01 maj 2025 17:05

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results 24 apr 2025 07:00

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes 23 apr 2025 15:00

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery 19 apr 2025 22:05

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 19 apr 2025 22:00

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025 31 mar 2025 23:00

Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 27 mar 2025 18:20

Resolutions from Zealand Pharma's Annual General Meeting 2025 25 mar 2025 17:00

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.20 mar 2025 17:00

Zealand Pharma increases its share capital as a result of the exercise of employee warrants 17 mar 2025 08:00

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity 12 mar 2025 07:00

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity 20 feb 2025 13:00

Zealand Pharma convenes its Annual General Meeting 2025 20 feb 2025 10:08

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024 20 feb 2025 07:00

Zealand Pharma Announces Financial Results for the Full Year 2024 13 feb 2025 17:00

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results 13 jan 2025 17:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 07 jan 2025 17:00

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity 06 jan 2025 17:00

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th 25 dec 2024 17:40

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 25 dec 2024 17:30

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.19 dec 2024 20:58

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome 10 dec 2024 15:00

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity 13 nov 2024 18:00

Zealand Pharma to participate in the Jefferies London Healthcare Conference 11 nov 2024 17:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 07 nov 2024 07:00

Zealand Pharma Announces Financial Results for the First Nine Months of 2024 01 nov 2024 17:30

Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results 09 okt 2024 00:45

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism 08 okt 2024 08:40

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide 30 sep 2024 17:00

Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 13 sep 2024 17:01

Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th 12 sep 2024 17:01

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants 09 sep 2024 17:01

Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide 30 aug 2024 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 30 aug 2024 17:00

Total number of shares and voting rights in Zealand Pharma on August 30, 2024 22 aug 2024 22:00

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants 16 aug 2024 18:05

Zealand Pharma major shareholder announcement: Bank of America Corporation 15 aug 2024 07:00

Zealand Pharma Announces Financial Results for the First Half of 2024 12 aug 2024 17:00

Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results 29 jul 2024 17:00

Zealand Pharma Appoints Eric Cox as Chief Commercial Officer 28 jun 2024 17:10

Zealand Pharma major shareholder announcement: Van Herk Investments 28 jun 2024 17:05

Total number of shares and voting rights in Zealand Pharma at June 28, 2024 28 jun 2024 08:36

Zealand Pharma completes registration of capital increase 26 jun 2024 00:35

Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion 25 jun 2024 20:43

Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion 25 jun 2024 17:02

Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion 20 jun 2024 17:37

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide 13 jun 2024 17:00

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants 07 jun 2024 10:38

Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis 06 jun 2024 12:29

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL 31 maj 2024 16:03

Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency 29 maj 2024 17:10

Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 29 maj 2024 13:32

Zealand Pharma major shareholder announcement: Polar Capital 23 maj 2024 20:45

Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide 16 maj 2024 07:00

Zealand Pharma Announces Financial Results for the First Quarter of 2024 12 maj 2024 22:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 09 maj 2024 16:00

Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results 19 apr 2024 22:20

Correction to Company announcement – No. 23 / 2024 19 apr 2024 17:05

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 19 apr 2024 17:00

Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 31 mar 2024 17:00

Total number of shares and voting rights in Zealand Pharma at March 31, 2024 26 mar 2024 22:05

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons 26 mar 2024 22:00

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants 21 mar 2024 18:00

Zealand Pharma major shareholder announcement: Van Herk Investments 20 mar 2024 17:39

Zealand Pharma's Annual General Meeting 2024 19 mar 2024 17:05

Zealand Pharma major shareholder announcement: Polar Capital 19 mar 2024 17:00

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons